MedTrace Logo

Study on Single-cell Regulons Atlas of Pancreatic Ductal Adenocarcinoma

NCT06720454 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2024-12-06

No results posted yet for this study

Summary

The first purpose of this study is to reveal the gene regulatory network of pancreatic cancer by analyzing single-cell transcriptome sequencing data and to draw a pancreatic cancer regulator map. In addition, bulk transcriptome sequencing data are combined to construct and verify the genetic prognostic model of pancreatic cancer regulators, providing clinical tools for accurate prognostic stratification and personalized treatment of pancreatic cancer patients. The second purpose of this study is to explore the molecular mechanism by which the key oncogene in the gene prognostic model promotes pancreatic cancer advance. New ideas and scientific basis are provided for finding potential molecular targets for the treatment of pancreatic cancer. Thus, the investigators included a Tissue Microarray (TMA)-based cohort of 68 PDAC patient tissue samples. TMA was obtained from OUTDO BIOTECH (Shanghai, China). The study was approved by the institutional review board, and ethics document number is YB M-05-01.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Molecular Prognostic Model
  • Regulons

Sponsors & Collaborators

  • Tiejun Ying

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-02
Primary Completion
2020-02-25
Completion
2024-04-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06720454 on ClinicalTrials.gov